

## A new sensitive indicator cell line reveals cross-transactivation of the viral LTR by gorilla and chimpanzee simian foamy viruses

Caroline Lambert, Réjane Rua, Antoine Gessain, Florence Buseyne

### ▶ To cite this version:

Caroline Lambert, Réjane Rua, Antoine Gessain, Florence Buseyne. A new sensitive indicator cell line reveals cross-transactivation of the viral LTR by gorilla and chimpanzee simian foamy viruses. Virology, 2016, 496, pp.219 - 226. 10.1016/j.virol.2016.06.010. pasteur-01414639

## HAL Id: pasteur-01414639 https://pasteur.hal.science/pasteur-01414639

Submitted on 16 Dec 2016  $\,$ 

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - ShareAlike 4.0 International License

#### VIRO-16-284-Revised

#### **Presented as short report**

A new sensitive indicator cell line reveals cross-transactivation of the viral LTR by gorilla and chimpanzee simian foamy viruses

Caroline Lambert<sup>a,b,c</sup>, Réjane Rua<sup>a\*</sup>, Antoine Gessain<sup>a,b</sup>, Florence Buseyne<sup>a,b,,#</sup>

<sup>a</sup> Unité d'épidémiologie et physiopathologie des virus oncogènes, Institut Pasteur, 28 rue du

Dr Roux, 75015 Paris, France

<sup>b</sup> UMR CNRS 3569, Institut Pasteur, Paris 75015, France

<sup>c</sup> Sorbonne Paris Cité, Cellule Pasteur, Université Paris Diderot, Institut Pasteur, 75015 Paris, France

\*Present address: Rejane Rua, Viral immunology and intravital imaging section, National Institute of Neurological Disorders and Stroke, National Institute of Health, Bethesda, Maryland, United States.

<sup>#</sup>Address correspondence to Florence Buseyne, florence.buseyne@pasteur.fr

The majority of currently identified simian foamy virus (SFV)-infected Cameroonian and Gabonese individuals harbor SFV from the gorilla lineage. We constructed an indicator cell line for the quantification of gorilla SFVs, in which the U3 sequence of a gorilla SFV directs the expression of the β-galactosidase protein. The gorilla foamy virus activated β-galactosidase (GFAB) cells efficiently quantified two zoonotic primary gorilla isolates and SFVs from three chimpanzee subspecies. Primary gorilla SFVs replicated more slowly and at lower levels than primary chimpanzee SFVs. Analysis of previously described motifs of Tas proteins and U3 LTRs involved in viral gene synthesis revealed conservation of such motifs in Tas proteins from gorilla and chimpanzee SFVs, but little sequence homology in the LTR regions previously shown to interact with viral and cellular factors.

Keywords: foamy viruses, Gorilla, zoonotic infection, viral transcription, long terminal repeat

Introduction

Foamy viruses (FVs) are complex retroviruses that infect nonhuman primates (NHPs), cats, cows, and horses (Kehl et al., 2013; Liu et al., 2013; Rethwilm and Bodem, 2013). Human infection occurs following cross-species transmission of simian foamy viruses (SFVs) with bites from infected animals representing the main route of infection (Betsem et al., 2011; Gessain et al., 2013; Khan, 2009; Rua and Gessain, 2015). SFVs establish lifelong infection in humans, with persistent detection of SFV DNA and SFV-specific antibodies in peripheral blood (Betsem et al., 2011; Cummins et al., 2005; Switzer et al., 2012). Neither pathogenicity nor human-to-human transmission of SFVs have yet been demonstrated. Human immunodeficiency viruses and human T-lymphotropic viruses have emerged from simian reservoirs, and cross-species transmission of simian retroviruses to humans is an ongoing process in many parts of the world (Locatelli and Peeters, 2012). The study of zoonotic SFV infection is relevant as a marker of exposure of humans to NHP pathogens and as a model to understand host-pathogen interactions in the new human host following cross-species transmission of retroviruses. SFVs also merit study for their own potential impact on human health, as vectors for gene therapy and vaccination (Olszko and Trobridge, 2013), and because co-infection with other retroviruses has been reported in humans (Filippone et al., 2015; Switzer et al., 2008). Such a co-infection with SFV has deleterious consequences in macaques experimentally infected with SIV (Choudhary et al., 2013).

We have been conducting epidemiological studies on SFVs in exposed human populations in Cameroon and Gabon, focusing both on risk factors of infection and viral characteristics. In these studies, about 75% of SFV-infected Central African hunters harbored an SFV strain from the gorilla lineage (Betsem et al., 2011; Calattini et al., 2007; Mouinga-Ondeme et al.,

2012). We previously set-up a gorilla SFV-specific quantitative PCR assay (Betsem et al., 2011) that allowed the detection of SFV DNA in blood and saliva cells and showed preferential tropism to both B and T lymphocytes (Rua et al., 2013; Rua et al., 2014). For historical reasons, the most studied SFV strains were derived from host-species housed in zoo and primate research centers, *i.e.* chimpanzee, macaques, and African green monkeys. In contrast, gorilla SFVs have been poorly studied despite infecting the majority of African individuals identified as carrying such viruses (Betsem et al., 2011; Calattini et al., 2007; Mouinga-Ondeme et al., 2012). A single study has reported the *in vitro* replication of a gorilla SFV (Bieniasz et al., 1995), of which the full length sequence was recently published (Schulze et al., 2011). We isolated two replication-competent gorilla SFVs from infected Cameroonian hunters and described their genetic characteristics (Rua et al., 2012) and also studied the genetic diversity of the *env* gene from 36 zoonotic gorilla SFVs (Richard et al., 2015).

Here, we aimed to conduct further studies that require quantification of replicating SFV. For this purpose, we have constructed an indicator cell line expressing the β-galactosidase protein under the control of a zoonotic gorilla SFV promoter, adapting a previously described method (Yu and Linial, 1993). This system was able to efficiently quantify cell infection with autologous SFV. This new cell line also efficiently quantified chimpanzee SFVs, revealing cross-transactivation of LTR-driven viral gene expression by heterologous SFV transactivator proteins. These properties offered the opportunity to compare primary SFV strains from both host-specific lineages as well as laboratory-adapted and primary chimpanzee SFVs.

#### Materials and Methods

#### Cells

Baby hamster kidney cells (BHK-21) were cultured in Dulbecco's modified Eagle medium (DMEM-Glutamax, Gibco, Courtaboeuf, France) supplemented with 5% fetal bovine serum (FBS, PAA Laboratories, Velizy Villacoublay, France). The foamy virus activated  $\beta$ -galactosidase (FAB) cells are BHK-21-derived cells containing the  $\beta$ -Galactosidase gene under the control of the LTR from SFVpsc-hu.PFV (Yu and Linial, 1993). They were cultured in DMEM supplemented with 5% fetal bovine serum and 50 µg/ml hygromycin B (Sigma-Aldrich, Lyon, France). The gorilla foamy virus activated  $\beta$ -galactosidase (GFAB) cells (described below) were cultured in DMEM supplemented with 5% fetal bovine serum and 50 µg/ml hygromycin B cells (described below) were cultured in DMEM supplemented with 5% fetal bovine serum and 300 µg/ml G418 (Sigma-Aldrich). We sequenced the LTR inserted in the FAB cell line to detect any possible sequence changes relative to Genbank sequence U21247.1. We found no nucleotide changes in the regions analyzed in the present study (data not shown).

#### Viruses

SFV isolates used for the study are presented in Table 1. The PFV (SFVpsc-hu.PFV) and SFV7 (SFVpve-7.pan2) strains were kindly provided by A. Saïb and A. Rethwilm. These strains have been extensively passaged *in vitro* and will be referred to as laboratory-adapted strains. Two chimpanzee, two gorilla, and one Cercopithecus SFV strain were isolated from peripheral blood cells of infected humans studied in our laboratory (Calattini et al., 2007; Rua et al., 2012). Original and first passage supernatants were used to produce the viral stocks used in this study, and these strains are referred to as primary strains.

The 653 nt long fragment of SFVggo-hu.BAK74 LTR (referred to as short U3 (S2) in (Rua et al., 2012)), homologous to the region from -533 to +20 nt of the HSRV13 molecular clone of SFVpsc-hu.PFV LTR (Yu and Linial, 1993), was inserted into the pCIneo plasmid (Promega) to replace the CMV promoter and the intron initially present. The coding sequence of the nuclear localization signal MPKKKRK from simian virus 40 T antigen was inserted between the LTR and  $\beta$ -Galactosidase coding sequence (optimized for expression in Hamster cells: 5'-ATGCCCAAGAAGAAAAGGAAA-3'). A neomycin resistance gene driven by an SV40 promoter was inserted into the plasmid for the purpose of selection in eukaryotic cells. This reporter plasmid, 140412-BAK, was transfected into BHK-21 cells using the LipoD293Reagent (SignaGen Laboratories, Rockville, MD, United States) according to the manufacturer's instructions. Twenty-four hours later, G418 was added (1 mg/ml) in culture medium and the cells were selected for 20 days. G418-resistant cells were seeded at 1, 0.5, and 0.25 cells/well in DMEM-5% FBS with 300 µg/ml G418. Forty clones were selected from 96-well plates with growing cells in less than 30% of the wells. These clones were screened for high level of X-Gal staining following infection with SFVggo-hu.BAK74 and SFVggo-hu.BAD468 strains and for the absence of staining of mock-infected cells. Of the 12 cellular clones specifically expressing  $\beta$ -galactosidase following gorilla SFV infection, one clone (# 35) was chosen on the basis of its high susceptibility to infection and stability over time, and was further amplified.

#### Detection of SFV-infected cells

Virus titers were determined by infecting GFAB cells at 30-40% confluence in flat bottom 96well plates with 30  $\mu$ l/well of serially diluted viral solutions prepared in DMEM. After a 2 h incubation, 170 µl of DMEM supplemented with 5% FBS were added to each well. Tests were performed in triplicate. The cells were fixed after 72 h with 0.5% glutaraldehyde in phosphate-buffered saline solution (PBS) for 10 min at room temperature (RT). Cells were washed with PBS and incubated 1 h at 37 °C with a X-Gal staining solution [2 mM MgCl<sub>2</sub>; 10 mM Potassium ferricyanide, 10 mM Potassium ferrocyanide; 0.5 mg/ml 5-Bromo-4-chloro-3-indolyl-B-D-galactopyranoside, in PBS]. An Ultimate UV Image analyzer (CTL Europe, Bonn, Germany) was used for counting stained cells. One infectious unit was defined as a blue cell or syncytia. Quantification was considered to be valid if the mean was > 30 cells/well and the coefficient of variation (CV = 100\*SD/mean) was < 30%.

#### Results

#### Construction of the GFAB cell line for the quantification of gorilla SFVs

The GFAB cell line was designed following the model of the FAB cell line that expresses the β-galactosidase gene under the transcriptional control of U3 sequences from the LTR of the HSRV13 molecular clone of SFVpsc-hu.PFV (Yu and Linial, 1993) (Figure 1A). This molecular clone harbors a deletion variant of LTR U3, referred to as short U3 (Schmidt et al., 1997). We selected the naturally occurring short LTR U3 from the primary SFVggo-hu.BAK74 strain (Rua et al., 2012), and inserted the sequence upstream of a nuclear localization signal and the β-galactosidase gene in a mammalian expression vector. We obtained stably-transfected BHK-21 cells. The reporter gene was expressed 72 h after infection with the autologous SFVggo-hu.BAK74 and blue cell foci were observed upon staining (Figure 1B). Similar results were obtained with another zoonotic primary gorilla isolate, SFVggo-hu.BAD468 (Figure 1B). Serial two-fold dilutions showed an overall linear relationship between 30 to 1000 infectious units/well (data not shown), although the best precision for automatic counting was

obtained for approximately 100-200 cells/well. The GFAB cells were infected at a moi of 0.02 (100 infectious units per P96 well ≈5000 cells) with several viral strains in triplicate on 12 different plates. The intraplate CV was from 3% to 27% (median 15%) and the interplate CV from 28% to 36% (median 30%) for this moi.

The GFAB cell line quantifies infection by both gorilla and chimpanzee SFVs.

We then tested the specificity of the GFAB and FAB cell lines for the detection of viral strains from various host-specific lineages. Four SFV isolates from three different chimpanzee subspecies (*Pan troglodytes schweinfurthii, P.t. verus* and *P.t. troglodytes*) efficiently transactivated the gorilla SFV LTR inserted in the GFAB cell line: the laboratory-adapted prototype PFV (SFVpsc-hu.PFV) and SFV7 (SFVpve-7.pan2) strains, and two primary zoonotic isolates (SFVptr-hu.AG15 and SFVptr-hu.BAD327) (Figure 2). The two primary zoonotic gorilla SFV strains reciprocally transactivated the chimpanzee SFVpsc-hu.PFV LTR inserted in the FAB cells, but the number of stained FAB cells was lower than that of stained GFAB cells (Figure 2). To confirm this finding, we quantified the same viral strains using a second indicator cell line constructed with another fragment of the short SFVpsc-hu.PFV LTR (Bieniasz et al., 1995). The viral titers were lower but proportional to those obtained with the FAB cells (data not shown). The primary Cercopithecus SFVcni-hu.AG16 isolate was not detected by the FAB or GFAB cells (Figure 2).

Although chimpanzee and gorilla SFV were able to transactivate the LTR from both the FAB and GFAB cell lines, the efficiency of cross-transactivation was not equivalent for both strains: the ratio of GFAB to FAB infected cells was close to one for the two laboratoryadapted chimpanzee isolates, approximately 1.5 for the two zoonotic chimpanzee isolates, and approximately three to five for the two zoonotic gorilla SFVs. In conclusion, efficient activation of a gorilla SFV LTR by heterologous chimpanzee SFVs was observed in GFAB cells, whereas the reciprocal interaction was detectable but weaker in FAB cells.

#### Sequences of Tas and LTR motifs from gorilla and chimpanzee SFVs

We searched for the molecular basis of the cross-transactivation of SFV LTRs by Tas proteins from different strains. A consensus DNA binding sequence common to simian, feline and bovine foamy viruses responsible for the interaction between the Tas protein and the LTR has been reported (Löchelt, 2003). Eight out of the eleven positions from this consensus sequence are fully conserved, and three harbor conservative changes between chimpanzee and gorilla SFVs (Figure 3A): L<sub>99</sub> versus F<sub>98</sub>, D<sub>144</sub> versus E<sub>143</sub> and I<sub>156</sub> versus V<sub>155</sub>. The R<sub>199</sub>H<sub>200</sub> motif involved in DNA binding (Ma et al., 2014) was conserved between both lineages. Further alignments of strains described in this work confirmed these observations (Supplementary Figure 1). In contrast, the Cercopithecus SFVcni-hu.AG16 strain that was not detected by either GFAB or FAB cells has a nonconservative H<sub>200</sub> to A<sub>200</sub> change as well as conservative changes in the consensus DNA binding motif. Altogether, previously defined functional motifs in the Tas protein were well conserved between chimpanzee and gorilla SFVs.

In the SFVpsc-hu.PFV U3 region proximal to the transcription initiation site, a Tas binding element has been mapped to position -65 to -35 by DNA footprinting and gel retardation analysis (He et al., 1996). This region contains a heptamer sequence shown to be essential for Tas binding by mutagenesis studies (He et al., 1996) as well as a stretch of 11 nucleotides conserved between chimpanzee and gorilla sequences (Schulze et al., 2011). However, these sequences were not conserved between SFVpsc-hu.PFV and SFVggo-hu.BAK74 (Figure 3B).

Additional differences in nucleotide sequences were present across the chimpanzee SFVs (Supplementary Figure 2).

Several, more distant and longer Tas responsive elements (TRE) and one negative regulatory element (NRE), have been described by analysis of reporter gene expression under the control of a mutated LTR (Erlwein and Rethwilm, 1993; Lee et al., 1993). The primary SFV U3 nucleotide sequences contained stretches of both conserved and variable sequences. Overall, the TRE sequences were not more conserved than non-TRE sequences (Figure 3B). The U3 of chimpanzee SFV contained three AP-1 binding sites (Maurer et al., 1991), of which two are mutated in gorilla SFVs. The putative Ets-1 binding site present in the short LTR U3 (Schmidt et al., 1997) was conserved in chimpanzee SFVs only. In conclusion, U3 sequences, proposed or shown to be response elements to viral and cellular transcription factors, were globally poorly conserved between SFV strains demonstrating cross-transactivation of promoters.

Gorilla SFVs replicate more slowly and at a lower level than chimpanzee SFVs

We titrated several SFV stocks using the GFAB cell line and normalized the production to the extent of cell layer destruction. Viral titers differed markedly between isolates: those of laboratory-adapted chimpanzee SFVs ranged from 105-106 IU/ml, those of primary chimpanzee SFVs from 104 to 105 IU/ml, and those of primary gorilla SFVs from 103 to 104 IU/ml. We titrated each viral stock at several time points using GFAB cells. There was no signal after 24 h. Gorilla SFV-infected cells were barely detectable after 48 h, but could be quantified 72 h post-infection. We detected significant viral titers (> 1000 infectious unit/ml) for chimpanzee SFVs after 48 h, which increased further after 72 h. Cell destruction after 96

Discussion

We generated a novel indicator cell line for the detection of SFVs, the GFAB cell line that encodes  $\beta$ -galactosidase under the control of a the U3 region from a gorilla SFV isolated in our laboratory. The GFAB cell line is able to detect gorilla SFV infection with high sensitivity as well as SFV isolates from another host-species lineage – chimpanzee. The sensitivity of the cell line was critical for the quantification of zoonotic primary gorilla SFVs with slow and/or low level replication. This tool will provide valuable information on strains that persistently infect humans and for molecular studies of these viruses.

The quantitative bioassay of viruses based on functional detection of an early synthesized viral protein is efficient for the detection of gorilla SFVs, consistent with results obtained with FV from several mammalian species (Jones-Engel et al., 2007; Stenbak et al., 2014; Zemba et al., 2000). Parallel titration showed similar sensitivity of GFAB and FAB cells for the quantification of chimpanzee SFVs, and a higher sensitivity of GFAB cells for the quantification of gorilla SFVs. The use of the same cell line to quantify several isolates is important to decrease assay variation due to variability in the ability of cell lines to support SFV entry and replication, and time-dependent evolution of cell lines over long term culture.

# Gorilla SFVs replicate more slowly and at lower levels than chimpanzee SFVs in GFAB cells

The only previous *in vitro* study of gorilla SFV was performed with the SFVggo-Gg strain isolated from a captive animal that was detected with a chimpanzee SFV indicator cell line (Bieniasz et al., 1995). Comparison of X-gal staining and cytopathic effect following culture with SFVggo-Gg-infected cells led to an estimated 10-fold lower transactivation of SFVpschu.PFV LTR by SFVggo-Gg than by chimpanzee strains (Bieniasz et al., 1995). Furthermore, SFVggo-Gg could only be detected after cell-mediated infection, but not after incubation with cell-free virus. We also report the lower and/or slower replication of gorilla SFVs relative to chimpanzee SFVs. The difference was not related to the zoonotic origin of gorilla strains, as primary zoonotic chimpanzee strains reached titers that were tenfold higher than those of the primary zoonotic gorilla SFVs. We also noted significant differences in viral titers between primary and laboratory-adapted chimpanzee SFVs. Cautious interpretation is needed when comparing viral isolates for which the properties could change during *in vitro* culture. Of note, viral stocks were produced from the primary viruses used in this study using vials from either the original stock or the first passage. Evolution during the 4-6 week period before obtainment of the first stock is limited, as shown by a comparison of the sequences from these viruses with those in the donor's buffy coat (Rua et al., 2012).

#### Cross-transactivation of viral LTRs by heterologous SFVs

One important result of this report is the transactivation of the LTR from a gorilla SFV by a chimpanzee SFV, and the transactivation of the LTR of a chimpanzee SFV by a gorilla SFV, albeit less efficiently. Furthermore, the four chimpanzee strains were isolated from three subspecies of chimpanzee SFVs and showed similar patterns of transactivation of the two U3 sequences tested. This functional conservation was observed despite overall low conservation of primary sequences of Tas protein and LTR. The percent identities were over 90% between gorilla SFVs, from 80 to 90% between chimpanzee SFVs from different animal subspecies, and from 55 to 70% between gorilla and chimpanzee SFVs (supplementary Figures 1 and 2). Chimpanzee SFVs cross-transactivated the heterologous LTR more efficiently than gorilla SFVs. This may reflect that gorilla SFVs have delayed and/or reduced synthesis of viral proteins relative to those of chimpanzee SFVs. It may also reflect the

binding of Tas proteins on distinct sequences in LTR from different host-specific SFV lineages. The cross-transactivation of LTR by heterologous viral strains is neither unique to gorilla and chimpanzee SFVs, nor restricted to strains from related host-species lineages: it was previously reported for macaque and Cercopithecus SFVs (Renne et al., 1993), for HIV and chimpanzee SFVs (Keller et al., 1992; Lee et al., 1992), and for HIV, SIV, and macaque SFVs (Mergia et al., 1992). However, no cross-transactivation has been observed between HTLV-1 and chimpanzee SFVs (Keller et al., 1991; Venkatesh et al., 1991), nor between primate and nonprimate FVs (Bodem et al., 2004; Omoto et al., 2004; Winkler et al., 1997).

The search for the molecular basis of cross-transactivation between gorilla and chimpanzee SFVs demonstrate the conservation of previously identified functional motifs in the Tas protein, whereas sequence homologies in the U3 TRE were difficult to find. In particular, the sequence previously identified as a functional Tas binding domain on the SFVpsc-hu.PFV (He et al., 1996) was not conserved between gorilla and chimpanzee SFVs. The absence of primary LTR sequence homology despite functional similarity is in agreement with previously published data. First, the sequences of TRE on LTRs and/or internal promoters present no or few homologies. Second, studies defining the DNA binding specificity of Tas to the internal promoter have illustrated the plasticity of the interaction between Tas and its DNA target as many nucleotide mutations did not affect this interaction, or even increased Tas-mediated transactivation (Kang and Cullen, 1998). Identification of sequence homologies related to cross-transactivation has been further hindered by the complexity of LTR regions from retroviruses that have numerous viral and cellular protein binding sites (Erlwein and Rethwilm, 1993; Lee et al., 1993), and by the lack of knowledge on the Tas-TRE binding mode.

Our observation raises the question of whether the interaction between Tas proteins and heterologous SFV LTR is an intrinsic property or depends upon extrinsic factors known to regulate transactivation: the lytic/persistence cellular infection state, cell-type specific factors, and U3 length polymorphisms. Indeed, the activity of the two SFV promoters differ in lytic and persistent infection *in vitro*, with higher internal promoter activity in persistently infected cells and higher LTR activity during lytic infection (Meiering et al., 2001). Activation of the SFV promoter varies in different cell lines, with up to 30-fold differences between the fibroblast cell line BHK and the lymphocytic Jurkat cells (Meiering et al., 2001). In addition, the presence of cell-type specific negative regulatory elements in LTR have been suggested through comparison of short and long LTR from SFVpsc-hu.PFV (Schmidt et al., 1997). Finally, length polymorphisms in U3 may affect their interaction with Tas protein. The U3 sequence used to construct the GFAB cell line is a deletion variant (Rua et al., 2012; Schmidt et al., 1997). *In vitro*, the various forms of the LTR are functional, with the full length LTR being possibly more sensitive to Tas protein (De Celis-Kosmas et al., 1997).

#### Conclusion

The novel GFAB cell line is a valuable research tool for gorilla and chimpanzee SFV quantification and the identification of key viral properties across primary strains. Here, we report differences between laboratory-adapted and primary viral strains. Our results underline the importance of extending current knowledge beyond the most studied prototype strain. Indeed, Tas interacts with promoters from host genes (Colas et al., 1995; Kido et al., 2002; Wagner et al., 2000; Wang et al., 2010), may be involved in clinically relevant interactions with lentiviruses (Choudhary et al., 2013), and is a potential (but still controversial) target of the immune system (Meiering and Linial, 2003; Regad et al., 2001).

#### **Funding information**

C. Lambert was personally supported by a doctoral grant from the French government program Investissement d'Avenir, laboratory of excellence, Integrative biology of emerging infectious diseases (LabEx IBEID). This work was supported by the Institut Pasteur in Paris, France, by the Programme Transversal de Recherche 437 from the Institut Pasteur, and by the Agence Nationale de la Recherche (grant ANR-10-LABX-62-IBEID; REEMFOAMY project, ANR 15-CE-15-0008-01). Funding agencies had no role in study design, the generation of results, or writing.

#### Acknowledgements

We thank Axel Rethwilm and Jochem Bodem for providing the SFV7 virus and BHLL cells, Ali Saïb and Joelle Tobaly-Papiero for providing the FAB cell line, Dirk Lindemann for providing the anti-Env hybridoma and Maxine Linial for her authorization to use this antibody. We are indebted to Arifa Khan for discussions and help with the strain nomenclature, and to Jochem Bodem for information on the SFVpsc-hu.PFV sequence verification. We thank S. Mercier and J.F. Musard from RD Biotech for discussions and construction of plasmid 140412-BAK, P. Souque for advice and help on transfection experiments. We thank members from the EPVO research unit for helpful discussions of data and critical reading of the manuscript.

## References

Achong, B.G., Mansell, P.W., Epstein, M.A., Clifford, P., 1971. An unusual virus in cultures from a human nasopharyngeal carcinoma. J Natl Cancer Inst 46, 299-307.

Betsem, E., Rua, R., Tortevoye, P., Froment, A., Gessain, A., 2011. Frequent and recent human acquisition of simian foamy viruses through apes' bites in Central Africa. PLoS Pathog 7, e1002306.

Bieniasz, P.D., Rethwilm, A., Pitman, R., Daniel, M.D., Chrystie, I., McClure, M.O., 1995. A comparative study of higher primate foamy viruses, including a new virus from a gorilla. Virology 207, 217-228.

Bodem, J., Kang, Y., Flügel, R.M., 2004. Comparative functional characterization of the feline foamy virus transactivator reveals its species specificity. Virology 318, 32-36.

Calattini, S., Betsem, E.B.A., Froment, A., Mauclere, P., Tortevoye, P., Schmitt, C., Njouom, R., Saib, A., Gessain, A., 2007. Simian foamy virus transmission from apes to humans, rural Cameroon. Emerg Infect Dis 13, 1314-1320.

Chang, J., Lee, K.J., Jang, K.L., Lee, E.K., Baek, G.H., Sung, Y.C., 1995. Human foamy virus Bel1 transactivator contains a bipartite nuclear localization determinant which is sensitive to protein context and triple multimerization domains. J Virol 69, 801-808.

Choudhary, A., Galvin, T.A., Williams, D.K., Beren, J., Bryant, M.A., Khan, A.S., 2013. Influence of naturally occurring simian foamy viruses (SFVs) on SIV disease progression in the Rhesus Macaque (Macaca mulatta) model. Viruses 5, 1414-1430.

Colas, S., Bourge, J.F., Wybier, J., Chelbi-Alix, M.K., Paul, P., Emanoil-Ravier, R., 1995. Human foamy virus infection activates class-I major histocompatibility complex antigen expression. J Gen Virol 76, 661-667.

Cummins, J.E., Boneva, R.S., Switzer, W.M., Christensen, L.L., Sandstrom, P., Heneine, W., Chapman, L.E., Dezzutti, C.S., 2005. Mucosal and systemic antibody responses in humans infected with simian foamy virus. J Virol 79, 13186-13189.

De Celis-Kosmas, J., Coronel, A., Grigorian, I., Emanoil-Ravier, R., Tobaly-Tapiero, J., 1997. Non-random deletions in human foamy virus long terminal repeat during viral infection. Arch Virol 142, 1237-1246.

Erlwein, O., Rethwilm, A., 1993. Bel-1 transactivator responsive sequences in the long terminal repeat of human foamy virus. Virology 196, 256-268.

Filippone, C., Betsem, E., Tortevoye, P., Cassar, O., Bassot, S., Froment, A., Fontanet, A., Gessain, A., 2015. A severe bite from a non-human primate is a major risk factor for HTLV-1 infection in hunters from Central Africa. Clin Infect Dis 60.

Gessain, A., Rua, R., Betsem, E., Turpin, J., Mahieux, R., 2013. HTLV-3/4 and simian foamy retroviruses in humans: Discovery, epidemiology, cross-species transmission and molecular virology. Virology 435, 187-199.

He, F., Sun, J.D., Garrett, E.D., Cullen, B.R., 1993. Functional organization of the Bel-1 transactivator of human foamy virus. J Virol 67, 1896-1904.

He, F.L., Blair, W.S., Fukushima, J., Cullen, B.R., 1996. The human foamy virus Bel-1 transcription factor is a sequence-specific DNA binding protein. J Virol 70, 3902-3908.

Jones-Engel, L., Steinkraus, K.A., Murray, S.M., Engel, G.A., Grant, R., Aggimarangsee, N., Lee, B., May, C., Schillaci, M.A., Somgird, C., Sutthipat, T., Vojtech, L., Zhao, J.Y., Linial, M.L., 2007. Sensitive assays for simian foamy viruses reveal a high prevalence of infection in commensal, free-ranging Asian monkeys. J Virol 81, 7330-7337.

Kang, Y., Cullen, B.R., 1998. Derivation and functional characterization of a consensus DNA binding sequence for the tas transcriptional activator of simian foamy virus type 1. J Virol 72, 5502-5509.

Kehl, T., Tan, J., Materniak, M., 2013. Non-simian foamy viruses: molecular virology, tropism and prevalence and zoonotic/interspecies transmission. Viruses 5, 2169-2209.

Keller, A., Garrett, E.D., Cullen, B.R., 1992. The Bel-1 protein of human foamy virus activates human immunodeficiency virus type-1 gene expression via a novel DNA target site. J Virol 66, 3946-3949.

Keller, A., Partin, K.M., Lochelt, M., Bannert, H., Flugel, R.M., Cullen, B.R., 1991. Characterization of the transcriptional trans activator of human foamy retrovirus. J Virol 65, 2589-2594.

Khan, A.S., 2009. Simian foamy virus infection in humans: prevalence and management. Expert Rev Anti-Infect Ther 7, 569-580.

Kido, K., Doerks, A., Lochelt, M., Flugel, R.M., 2002. Identification and functional characterization of an intragenic DNA binding site for the spumaretroviral trans-activator in the human p57(Kip2) gene. J Biol Chem 277, 12032-12039.

Lee, A.H., Lee, K.J., Kim, S.Y., Sung, Y.C., 1992. Transactivation of human immunodeficiency type 1 long terminal repeat-directed gene-expression by the human foamy virus bel1 protein requires a specific DNA sequence. J Virol 66, 3236-3240.

Lee, K.J., Lee, A.H., Sung, Y.C., 1993. Multiple positive and negative cis-acting elements that mediate transactivation by bel 1 in the long terminal repeat of human foamy virus. J Virol 67, 2317-2326.

Liu, W., Lei, J., Liu, Y., Lukic, D.S., Raethe, A.-M., Bao, Q., Kehl, T., Bleiholder, A., Hechler, T., Löchelt, M., 2013. Feline foamy virus-based vectors: advantages of an authentic animal model. Viruses 5, 1702-1718.

Locatelli, S., Peeters, M., 2012. Cross-species transmission of simian retroviruses: how and why they could lead to the emergence of new diseases in the human population. AIDS 26, 659-673.

Löchelt, M., 2003. Foamy virus transactivation and gene expression. Curr Top Microbiol Immunol 277, 27-61.

Löchelt, M., Zentgraf, H., Flügel, R.M., 1991. Construction of an infectious DNA clone of the full-length human spumaretrovirus genome and mutagenesis of the bel1 gene. Virology 184, 43-54.

Ma, Q., Tan, J., Cui, X., Luo, D., Yu, M., Liang, C., Qiao, W., 2014. Residues R199H200 of prototype foamy virus transactivator Bel1 contribute to its binding with LTR and IP promoters but not its nuclear localization. Virology 449, 215-223.

Materniak, M., Kubiś, P., Rola – Łuszczak, M., Khan, S.A., Buseyne, F., Lindemann, D., Löchelt , M., Kuźmak, J., 2015. Tenth International Foamy Virus Conference 2014 – achievements and perspectives. Viruses 7, 1651-1666.

Maurer, B., Serfling, E., Termeulen, V., Rethwilm, A., 1991. Transcription factor AP-1 modulates the activity of the human foamy virus long terminal repeat. J Virol 65, 6353-6357.

Meiering, C.D., Linial, M.L., 2003. The promyelocytic leukemia protein does not mediate foamy virus latency in vitro. J Virol 77, 2207-2213.

Meiering, C.D., Rubio, C., May, C., Linial, M.L., 2001. Cell-type-specific regulation of the two foamy virus promoters. J Virol 75, 6547-6557.

Mergia, A., Prattlowe, E., Shaw, K.E.S., Renshawgegg, L.W., Luciw, P.A., 1992. Cis-acting regulatory regions in the long terminal repeat of simian foamy virus type 1. J Virol 66, 251-257.

Mouinga-Ondeme, A., Caron, M., Nkoghe, D., Telfer, P., Marx, P., Saib, A., Leroy, E., Gonzalez, J.P., Gessain, A., Kazanji, M., 2012. Cross-species transmission of simian foamy virus to humans in rural Gabon, Central Africa. J Virol 86, 1255-1260.

Olszko, M.E., Trobridge, G.D., 2013. Foamy virus vectors for HIV gene therapy. Viruses 5, 2585-2600.

Omoto, S., Brisibe, E.A., Okuyama, H., Fujii, Y.R., 2004. Feline foamy virus Tas protein is a DNA-binding transactivator. J Gen Virol 85, 2931-2935.

Regad, T., Saib, A., Lallemand-Breitenbach, V., Pandolfi, P.P., de The, H., Chelbi-Alix, M.K., 2001. PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator. EMBO J 20, 3495-3505.

Renne, R., Mergia, A., Renshaw-Gegg, L.W., Neumann-Haefelin, D., Luciw, P.A., 1993. Regulatory elements in the long terminal repeat (LTR) of simian foamy virus type 3 (SFV-3). Virology 192, 365-369.

Rethwilm, A., Bodem, J., 2013. Evolution of foamy viruses: the most ancient of all retroviruses. Viruses 5, 2349-2374.

Richard, L., Rua, R., Betsem, E., Mouinga-Ondeme, A., Kazanji, M., Leroy, E., Njouom, R., Buseyne, F., Afonso, P.V., Gessain, A., 2015. Cocirculation of two env molecular variants, of possible recombinant origin, in gorilla and chimpanzee simian foamy virus strains from Central Africa. J Virol 89, 12480-12491.

Rogers, N.G., Basnight, M., Gibbs, C.J., Gajdusek, D.C., 1967. Latent viruses in chimpanzees with experimental kuru. Nature 216, 446-449.

Rua, R., Betsem, E., Calattini, S., Saib, A., Gessain, A., 2012. Genetic characterization of simian foamy viruses infecting humans. J Virol 86, 13350-13359.

Rua, R., Betsem, E., Gessain, A., 2013. Viral latency in blood and saliva of simian foamy virusinfected humans. PLoS One 8, e77072.

Rua, R., Betsem, E., Montange, T., Buseyne, F., Gessain, A., 2014. In vivo cellular tropism of gorilla simian foamy virus in blood of infected humans. J Virol 88, 13429-13435.

Rua, R., Gessain, A., 2015. Origin, evolution and innate immune control of simian foamy viruses in humans. Curr Opin Virol 10, 47-55.

Schmidt, M., Herchenroder, O., Heeney, J., Rethwilm, A., 1997. Long terminal repeat U3 length polymorphism of human foamy virus. Virology 230, 167-178.

Schulze, A., Lemey, P., Schubert, J., McClure, M.O., Rethwilm, A., Bodem, J., 2011. Complete nucleotide sequence and evolutionary analysis of a gorilla foamy virus. J Gen Virol 92, 582-586.

Stenbak, C.R., Craig, K.L., Ivanov, S.B., Wang, X., Soliven, K.C., Jackson, D.L., Gutierrez, G.A., Engel, G., Jones-Engel, L., Linial, M.L., 2014. New World simian foamy virus infections in vivo and in vitro. J Virol 88, 982-991.

Switzer, W.M., Garcia, A.D., Yang, C.F., Wright, A., Kalish, M.L., Folks, T.M., Heneine, W., 2008. Coinfection with HIV-1 and simian foamy virus in West Central Africans. J Infect Dis 197, 1389-1393.

Switzer, W.M., Tang, S.H., Ahuka-Mundeke, S., Shankar, A., Hanson, D.L., Zheng, H.Q., Ayouba, A., Wolfe, N.D., LeBreton, M., Djoko, C.F., Tamoufe, U., Esteban, A., Heneine, W., Peeters, M., Wright, L.L., Muyembe-Tamfum, J.J., Wemakoy, E.O., Mulembakani, P., Hoff, N.A., Rimoin, A.W., 2012. Novel simian foamy virus infections from multiple monkey species in women from the Democratic Republic of Congo. Retrovirology 9, 100.

Venkatesh, L.K., Chinnadurai, G., 1993. The carboxy-terminal transcription enhancement region of the human spumaretrovirus transactivator contains discrete determinants of the activator function. J Virol 67, 3868-3876.

Venkatesh, L.K., Theodorakis, P.A., Chinnadurai, G., 1991. Distinct cis-acting regions in U3 regulate transactivation of the human spumaretrovirus long terminal repeat by the viral bel1 gene product. Nucl Acids Res 19, 3661-3666.

Wagner, A., Doerks, A., Aboud, M., Alonso, A., Tokino, T., Flugel, R.M., Lochelt, M., 2000. Induction of cellular genes is mediated by the Bel1 transactivator in foamy virus-infected human cells. J Virol 74, 4441-4447.

Wang, J., Tan, J., Zhang, X., Guo, H., Zhang, Q., Guo, T., Geng, Y., Qiao, W., 2010. BFV activates the NF-kB pathway through its transactivator (BTas) to enhance viral transcription. Virology 400, 215-223.

Winkler, I., Bodem, J., Haas, L., Zemba, M., Delius, H., Flower, R., Flugel, R.M., Lochelt, M., 1997. Characterization of the genome of feline foamy virus and its proteins shows distinct features different from those of primate spumaviruses. J Virol 71, 6727-6741.

Yu, S.F., Linial, M.L., 1993. Analysis of the role of the bel and bet open reading frames of foamy virus by using a new quantitative assay. J Virol 67, 6618-6624.

Zemba, M., Alke, A., Bodem, J., Winkler, I.G., Flower, R.L.P., Pfrepper, K.I., Delius, H., Flugel, R.M., Lochelt, M., 2000. Construction of infectious feline foamy virus genomes: Cat antisera do not cross-neutralize feline foamy virus chimera with serotype-specific env sequences. Virology 266, 150-156.

#### **Figure Legends**

Figure 1. The GFAB cell line. A. Principle of the GFAB indicator cell line 1. Schematic representation of the transgene stably transfected into BHK-21 cells: the 653 nt long fragment of SFVggo-hu.BAK74 LTR (referred to as short U3 (S2) in (Rua et al., 2012)), homologous to the -533 to +20 nt region of the HSRV13 molecular clone of SFVpsc-hu.PFV LTR (Yu and Linial, 1993), was inserted in the pCIneo plasmid (Promega), followed by the coding sequence of the nuclear localization signal (NLS)MPKKKRK, and the β-Galactosidase coding sequence; 2. Upon viral infection, the viral transactivator protein Tas activates the synthesis of  $\beta$ -galactosidase mRNA; 3. After 72 h of infection, the  $\beta$ -galactosidase protein is detected through the addition of its chromogenic substrate, X-gal, into the wells, leading to the blue staining of SFV-infected cells; 4. Infectious units (blue cells or syncytia) are numerated by an image analyser: photographs show a stained well and an analyzed photograph where counted cells are surrounded by an orange line. B. GFAB cells were infected by two gorilla SFV isolates or mock infected, as indicated in the above scheme. After 72 h of infection, the cells were fixed and stained as described in the materials and methods section. Pictures from light microscope, magnification 250X.

**Figure 2. GFAB and FAB cells detect both chimpanzee and gorilla SFV infections.** Viral stocks from chimpanzee and gorilla SFVs were titrated on the GFAB cell line. Then, GFAB and FAB cells were infected at a moi of 0.02. After 72 h of infection, the cells were fixed, stained and counted. An undiluted stock of SFVcni-hu.AG16 was used as a negative control. Pictures from the Ultimate UV Image analyzer are shown side by side for GFAB (left) and FAB cell line (right) for one representative experiment. The viral strain and the number of stained cells are indicated above the photographs.

#### Figure 3. Tas protein and LTR functional motifs from SFVggo-hu.BAK74 and SFVpsc-hu.PFV.

A. The Tas central DNA binding domain (BD) and the nuclear localization signal (NLS) from SFVpsc-hu.PFV (aa 89-223) and SFVggo-hu.BAK74 (aa 88-222) were aligned. Functional motifs are superimposed on the sequences: the consensus DNA binding sequence proposed for primate and nonprimate foamy viruses (Löchelt, 2003) and the R<sub>199</sub>H<sub>200</sub> motif (Ma et al., 2014). Amino acid changes in these motifs are indicated with red characters. Identical residues are shown as dots.

B. The 5'LTR U3 and beginning of R regions from SFVpsc-hu.PFV(HSRV13) (Genbank U21247.1) and SFVggo-hu.BAK74 (GenBank JQ867464) were aligned. Sequences transduced into FAB and GFAB cells are indicated by the blue arrows. Dots indicate identity, gaps are represented in yellow, and the numbers used for motif description are those from SFVpschu.PFV(HSRV13). The transcription initiation start and TATA box are highlighted in red. In the U3 region proximal to the transcription initiation site, the Tas binding element (TBE) at position -65 to -35 (He et al., 1996) is highlighted in grey. Within this TBE, the heptamer sequence conserved in the LTR and internal promoter from SFVpsc-hu.PFV (He et al., 1996), and the -58 to -47 nucleotide sequence conserved with SFVggo-Gg (Schulze et al., 2011) are highlighted. Several, more distant and longer Tas responsive elements, and one negative regulatory element (NRE), are highlighted in purple and named according to their original description (BRE stands for bel-1-responsive elements, (Erlwein and Rethwilm, 1993; Lee et al.)). Binding sites for cellular transcription factors are highlighted in green: three AP-1 binding sites (Maurer et al., 1991) and the first of the two putative Ets-1 binding sites (Schmidt et al., 1997). The second Ets-1 site was absent in the studied viruses. Alignments were performed using CLC Main Workbench software.

#### Table 1: Viral strains used in the study.

Virus <sup>1</sup>	Nonhuman primate host species	Isolated from human sample	Genbank accession number	First description
SFVpsc-hu.PFV	Pan troglodytes schweinfurthii	Yes	Y07725.1	(Achong et al., 1971)
SFVpsc- hu.PFV(HSRV13)	Pan troglodytes schweinfurthii (Molecular clone HSRV13)		U21247.1	(Löchelt et al., 1991)
SFVpve-7.Pan2	Pan troglodytes verus	No	U04327.1	(Rogers et al., 1967)
SFVptr-hu.BAD327	Pan troglodytes trogodytes	Yes	JQ867463.1	(Rua et al., 2012)
SFVptr-hu.AG15	Pan troglodytes trogodytes	Yes	JQ867462.1	(Calattini et al., 2007)
SFVggo-hu.BAK74	Gorilla gorilla gorilla	Yes	JQ867464.1	(Rua et al., 2012)
SFVggo-hu.BAD468	Gorilla gorilla gorilla	Yes	JQ867465.1	(Rua et al., 2012)
SFVcni-hu.AG16	Cercopithecus <mark>n</mark> ictitans	Yes	JQ867466.1	(Calattini et al., 2007)

<sup>1</sup> According to the last update of FV taxonomy and development of a consensus nomenclature of virus isolates that was discussed at the 10<sup>th</sup> International Foamy Virus Conference (2014) in Pulawy, Poland (Materniak et al., 2015).

## Supplemental material presented in the pdf file Lambert\_Virology\_Supplementaldata.pdf

## Supplementary figure 1: Percent amino acid identity and functional motifs in SFV Tas proteins.

We aligned Tas protein sequences from isolates tested in our study or related to them: SFVpsc-hu.PFV, SFVpve (as the SFVpve-7.Pan2 Tas sequence was not available), SFVptrhu.AG15, SFVptr-hu.BAD327, SFVggo-Gg, SFVggo-hu.BAK74, SFVggo-hu.BAD468, and SFVcnihu.AG16 that we used as a control in several experiments. Percent amino acid identity are shown for full length Tas proteins (panel A) and its 3 functional domains (B: shared domain, C: DNA binding domain, D: activation domain). The background color indicates levels of identity, where red corresponds to the most highly conserved sequences and blue to the least conserved sequences. Panel E presents known functional motifs superimposed on the sequences. Gap residues are shown in yellow, identical residues are shown as dots, and positions of motifs are indicated relative to the SFVpsc-hu.PFV sequence. The consensus DNA binding sequence proposed for primate and nonprimate foamy viruses(DNA BD, (Löchelt, 2003)), highlighted in red, was fully conserved across the eight isolates, except at three positions, where conservative changes were found in the three gorilla SFVs: at positions 96 (L to F), 144 (L to D), and 156 (I to V). The Cercopithecus SFVcni-hu.AG16 strain had conservative changes at positions 144 and 156. The RH motif at position 199-200, highlighted in blue, was proposed to be the first part of a bipartite nuclear localization signal (Chang et al., 1995) and subsequently shown to be involved in DNA binding (Ma et al., 2014). This motif was conserved in all isolates except SFVcni-hu.AG16. The three R/K residues at position 221 to 223, highlighted in green, were proposed to be the second part of the nuclear localization signal (Chang et al., 1995). These residues were conserved in chimpanzee SFVs. The primary sequences were different in gorilla and Cercopithecus SFVs, but this region contained two stretches of basic residues that constitute a putative nuclear localization signal, as previously described (Rua et al., 2012). The minimal conserved activation motif at position 273 to 287 (He et al., 1993; Venkatesh and Chinnadurai, 1993), highlighted in grey, was highly conserved, with one nonconservative change (E to K) in SFVpve at position 284, one conservative change (I to Y) at position 287 in the 3 gorilla SFVs, and two nonconservative changes in the Cercopithecus SFV isolate: E to Q at position 281 and G to N at position 284. Alignments were performed using CLC Main Workbench software.

#### Supplementary figure 2: Percent identity and functional motifs in SFV LTRs.

We aligned LTR sequences from isolates tested in our study or related to them: SFVpschu.PFV (full length LTR), the HSRV13 molecular clone of SFVpsc-hu.PFV (SFVpsc-hu.HSRV13, with a short U3 form, inserted in the FAB cell line (Yu and Linial, 1993)), from SFVpve (as the SFVpve-7.Pan2 LTR sequence was not available), SFVptr-hu.AG15, SFVptr-hu.BAD327, SFVggo-Gg, SFVggo-hu.BAK74, SFVggo-hu.BAD468, and SFVcni-hu.AG16 that we used as a control in cross-transactivation experiments. The percent nucleotide identity is shown for the whole U3, the last 70 nt of the U3, R, and U5 regions (panels A to D) of the nine SFV sequences. The background color indicates the level of identity, where red corresponds to the most highly conserved sequences and blue to the least conserved sequences. In panel E, we superimposed regions shown or predicted to interact with viral Tas protein or cellular factors. The blue arrows indicate the beginning of the LTR fragments inserted in the FAB and GFAB cell lines. The transcription initiation start and TATA box are highlighted in red (Rua et

al., 2012). In the U3 region proximal to the transcription initiation site, we show the Tas binding element (TBE) at position -65 to -35, highlighted in grey (He et al., 1996), that contained an heptamer sequence conserved in LTR and internal promoter from SFVpschu.PFV (He et al., 1996), and the conserved sequence at position -58 to -47 proposed at the time of the SFVggo-Gg sequence description (Schulze et al., 2011). These sequences were partially conserved across chimpanzee and gorilla SFV LTRs. Several, more distant and longer Tas responding elements (named BRE for bel-1 responsive elements) and one negative regulatory element (NRE) are highlighted in purple (Erlwein and Rethwilm, 1993; Lee et al.). Overall, primary nucleotide sequences in these regions differed considerably between chimpanzee and gorilla SFVs. Cellular transcription factors are highlighted in green. The three AP-1 binding sites described in SFVpsc-hu.PFV (Maurer et al., 1991) were conserved in all chimpanzee SFVs. Only the third AP-1 binding site was present in the gorilla SFVs, and none were present in SFVcni-hu.AG16. Two putative Ets-1 binding sites have been proposed by Schmidt et al. (Schmidt et al., 1997). The first one was conserved in the chimpanzee SFV only. The second Ets-1 site was deleted in the three viruses with a short U3 (SFVpschu.HSRV13, SFVggo-Gg and SFVggo-hu.Bak74), in the SFvcni-hu.AG16 strain, and was mutated in the other viruses. Alignments were performed using CLC Main Workbench software.

#### Figure Click here to download high resolution image







#### Figure Click here to download high resolution image



Supplementary figure 1: Percent amino acid identity and functional motifs in SFV Tas proteins.

A. Tas protein (full length)

		1	2	3	4
SFVpsc-hu.PFV-Tas	1		86,00	91,67	88,00
SFVpve-Tas	2	86,00		83,67	80,67
SFVptr-hu.BAD327-Tas	3	91,67	83,67		96,33
SFVptr-hu.AG15-Tas	4	88,00	80,67	96,33	
SFVggo-Tas	5	66,00	62,33	64,67	62,00
SFVggo-hu.BAK74 -Tas	6	65,33	61,67	64,33	61,67
SFVggo-hu.BAD468-Tas	7	64,67	61,67	64,67	62,00
SFVcni-hu.AG16-Tas	8	37,83	36,51	37,83	37,50

#### B. Tas protein, shared domain (aa 1-88)

		-				-			
		1	2	3	4	5	6	7	8
.PFV-Tas	1		88,64	90,91	82,95	70,45	69,32	68,18	21,98
Vpve-Tas	2	88,64		88,64	81,82	63,64	64,77	63,64	20,88
)327-Tas	3	90,91	88,64		92,05	63,64	64,77	65,91	23,08
G15-Tas	4	82,95	81,82	92,05		57,95	59,09	60,23	21,98
/ggo-Tas	5	70,45	63,64	63,64	57,95		97,70	97,70	24,18
K74 -Tas	6	69,32	64,77	64,77	59,09	97,70		97,70	23,08
)468-Tas	7	68,18	63,64	65,91	60,23	97,70	97,70		24,18
G16-Tas	8	21,98	20,88	23,08	21,98	24,18	23,08	24,18	

5

66,00

62,33

64,67

62,00

97,99

97,32

33,55

6

65,33

61,67

64,33

61,67

97,99

97,32

32,89

7

64,67

61,67

64,67

62,00

97,32

97,32

33,55

8

37,83

36,51

37,83

37,50

33,55

32,89

33,55

SFVpsc-hu.PFV-Ta: SFVpve-Ta: SFVptr-hu.BAD327-Ta: SFVptr-hu.AG15-Ta: SFVggo-hu.BAD468-Ta: SFVggo-hu.BAD468-Ta: SFVggo-hu.BAD468-Ta:

#### C. Tas Protein, DNA binding domain (aa 89-200)

		1	2	3	4	5	6	7	8
as	1		85,71	91,96	91,07	65,18	65,18	66,07	49,11
as	2	85,71		81,25	80,36	66,07	66,07	66,96	47,32
as	3	91,96	81,25		99,11	66,07	66,07	66,96	47,32
as	4	91,07	80,36	99,11		65,18	65,18	66,07	47,32
as	5	65,18	66,07	66,07	65,18		100,00	98,21	40,18
as	6	65,18	66,07	66,07	65,18	100,00		98,21	40,18
as	7	66,07	66,96	66,96	66,07	98,21	98,21		41,07
as	8	49,11	47,32	47,32	47,32	40,18	40,18	41,07	

SFVpsc-hu.PFV-Tas SFVpve-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.AG15-Tas SFVggo-Tas SFVggo-hu.BAK74 -Tas SFVggo-hu.BAD468-Tas SFVggo-hu.BAD468-Tas

#### D. Tas protein, C terminal domain (aa 201-300)

		1	2	3	4	5	6	7	8
.PFV-Tas	1		84,00	92,00	89,00	63,00	62,00	60,00	39,60
Vpve-Tas	2	84,00		82,00	80,00	57,00	54,00	54,00	38,61
)327-Tas	3	92,00	82,00		97,00	64,00	62,00	61,00	40,59
G15-Tas	4	89,00	80,00	97,00		62,00	60,00	59,00	40,59
/ggo-Tas	5	63,00	57,00	64,00	62,00		96,00	96,00	34,65
K74 -Tas	6	62,00	54,00	62,00	60,00	96,00		96,00	33,66
0468-Tas	7	60,00	54,00	61,00	59,00	96,00	96,00		33,66
G16-Tas	8	39,60	38,61	40,59	40,59	34,65	33,66	33,66	

SFVpsc-hu.PFV-Tas SFVpve-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.AG15-Tas SFVggo-Tas SFVggo-hu.BAK74 -Tas SFVggo-hu.BAD468-Tas SFVcni-hu.AG16-Tas

SFVpsc-hu.PFV-Tas	MDSYEKEESVAST SGIQDLQTLSELVGPENAGEGELTIAEEPEENPRRPRRYTKREVKCVSYH - AYKEIEDKHP 73
SFVpve-Tas	QE. P
SFVptr-hu.BAD327-Tas	QE
SFVptr-hu.AG15-Tas	QE
SFVqqo-Tas	
SFVggo-hu.BAD468-Tas	
SFVago-hu.BAK74 -Tas	
SEVcni-hu AG16-Tas	ATW EKKELTHINGE DDP TE I IDID MDPN GPDONPGG KINIQISN PGNTSEKT GEGEMDK EQD 76
SFVpsc-hu.PFV-Tas	QHIKLQDWIPTPEEMSKSLCKR <mark>U</mark> ILCGLYSAEKASE <mark>U</mark> LRMPFTVSWEQSDTDPDCFIVS <mark>M</mark> T <mark>O</mark> IF <mark>O</mark> DAVIHDPMPIR 149
SFVpve-Tas	HKIIGGKE.NE.N
SFVptr-hu.BAD327-Tas	
SFVptr-hu.AG15-Tas	КТ
SFVggo-Tas	NLHN
SFVggo-hu.BAD468-Tas	NLHN
SFVggo-hu.BAK74 -Tas	NLHN
SFVcni-hu.AG16-Tas	D-L.MRV.E.DKWA.I.MN.QGSFNYDIHKE.K.F.E.E.H.KM.MT.L.EVK 151
	Consensus DNA BD INI S& DNA BD INI S
SFVpsc-hu.PFV-Tas	WDPEVG <mark>II</mark> WVKYKPLR <mark>G</mark> IVGSAVFIMH <mark>KH</mark> DRN <mark>G</mark> SLVKPSTSRSEGPKPRP <mark>RH</mark> DPVLRCDMFEKHHKPRQKRP <mark>RRR</mark> SI 225
SFVpsc-hu.PFV-Tas SFVpve-Tas	WDPEVGIIWVKYKPLRGIVGSAVFIMHKHDRNCSLVKPSTSRSEGPKPRPRHDPVLRCDMFEKHHKPRQKRPRRRSI225 
SFVpsc-hu.PFV-Tas SFVpve-Tas SFVptr-hu.BAD327-Tas	WDPEVGIIWVKYKPLRGIVGSAVFIMHKHORNGSLVKPSTSRSEGPKPRPRHDPVLRCDMFEKHHKPRQKRPRRRSI225
SFVpsc-hu.PFV-Tas SFVpve-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.AG15-Tas	WDPEVGIMVVKYKPLRGIVGSAVFIMHKHQRNCSLVKPSTSRSEGPKPPRR       DPVLRCDMFEKHHKPRQKRPRRRSI225
SFVpsc-hu.PFV-Tas SFVpve-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.AG15-Tas SFVggo-Tas	WDPEVGIWVKYKPLRCIVGSAVFIMHKHDRNCSLVKPSTSRSEGPKPRPRHDPVLRCDMFEKHHKPRQKRPRRRSI225
SFVpsc-hu.PFV-Tas SFVpve-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.AG15-Tas SFVggo-Tas SFVggo-hu.BAD468-Tas	WDPEVGIWVKYKPLRGIVGSAVFIMHKHDRNGSLVKPSTSRSEGPKPRPRHDPVLRCDMFEKHHKPRQKRPRRRSI225     S.E.   E.K.     K.   CP     K.   F.     VOR   F.     YNAD   Y.     V.   M.K.     K.   CFI     YNAD.   Y.     Y.   Y.     YNAD.   Y.     Y.   Y.
SFVpsc-hu.PFV-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.AG15-Tas SFVptr-hu.AG15-Tas SFVggo-hu.BAD468-Tas SFVggo-hu.BAV468-Tas	WDPEVGIIWVKYKPLRGIVGSAVFIMHKHDRNGSLVKPSTSRSEGPKPRPRHDPVLRCDMFEKHHKPRQKRPRRRSI225     S. E.   E.   K.   CP   R.   P. S.K.   225     K.   F.   Y   K.   E.   K.   225     K.   F.   Y   K.   E.   K.   225     YNAD.   YNAD.   V.   M.K.   EK.   CFI.   P. KQ.   KA.   RNY.   P.   PGP.   224     YNAD.   V.   IN.   V.   M.K.   EK.   CFI.   P. KQ.   KA.   RNY.   P.   PGP.   224     YNAD.   V.   IN.   V.   M.K.   EK.   CFI.   P. KQ.   KA.   RNY.   P.   PGP.   224     YNAD.   Y.   FNR.   V.   M.K.   EK.   CFI.   P. KQ.   KA.   RNY.   PGP.   224
SFVpsc-hu.PFV-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.AG15-Tas SFVggo-hu.BAD468-Tas SFVggo-hu.BAD468-Tas SFVggo-hu.BAK74 -Tas SFVcni-hu.AG16-Tas	WDPEVGIIWVKYKPLRGIVGSAVFIMHKHDRNGSLVKPSTSRSEGPKPRPRHDPVLRCDMFEKHHKPRQKRPRRRSI225     S. E.   E.   F.   CP   R.   P.S.K.   225     K.   F.   Y.   F.   Y.   K.   225     YNAD.   Y.   FNR.   Y.   K.   E.   K.   225     YNAD.   Y.   FNR.   Y.   K.   E.   K.   225     YNAD.   Y.   FNR.   Y.   K.   E.   K.   225     YNAD.   Y.   FNR.   Y.   Y.   K.   E.   K.   225     YNAD.   Y.   FNR.   Y.   M.K.   EK.   CFI.   P.KQ.   KA.   RNY.   P.   PGP.   224     YNAD.   Y.   M.K.   EK.   CFI.   P.KQ.   KA.   RNY.   P.GP.   224     YNAD.   Y.   M.K.   EK.   CFI.   P.KQ.   KA.   RNY.   P.GP.   224     YNAD.   Y.   M.K.   EK.   CFI.   P.KQ.   KA.   RNY.   PGP.   224
SFVpsc-hu.PFV-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.AG15-Tas SFVggo-hu.BAD468-Tas SFVggo-hu.BAD468-Tas SFVggo-hu.BAK74 -Tas SFVcni-hu.AG16-Tas	WDPEVGIIWVKYKPLRGIVGSAVFIMHKHDRNGSLVKPSTSRSEGPKPRPRHDPVLRCDMFEKHHKPRQKRPRRRSI225     S. E.   E.   F.   CP   R.   P. S. K.   225     K.   F.   Y.   F.   Y.   K.   225     YNAD.   Y.   F.R.   Y.   K.   K.   225     YNAD.   Y.   M.K.   EK.   CFI   P.KQ   KA.   RNY   P.   PGP   224     YNAD.   Y.   M.K.   EK.   CFI   P.KQ   KA.   RNY   P.   PGP   224     YNAD.   Y.   M.K.   EK.   CFI   P.KQ   KA.   RNY   P.   PGP   224     YNAD.   Y.   M.K.   EK.   CFI   P.KQ   KA.   RNY <td< th=""></td<>
SFVpsc-hu.PFV-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.AG15-Tas SFVggo-Tas SFVggo-hu.BAD468-Tas SFVggo-hu.BAK74 -Tas SFVggo-hu.BAK74 -Tas	WDPEVGI WVKYKPLRG I VGSAVF I MHKHDRNG SLVKPSTSRSEGPKPRPRHDPVLRCDMFEKHHKPRQKRPRRRS I 225     S. E.   P. S.K.     K.   CP     K.   P. S.K.     YNAD.   FRR.     V.   M.K.     EK.   CFI     YNAD.   V.     K.   CFI     YNAD.   V.     V.   M.K.     EK.   CFI     P.KQ.   KA.     YNAD.   V.     V.   M.K.     EK.   CFI     VAD.   V.     V.   M.K.     EK.   CFI     V.   M.K.     EK.   CFI     P.KQ.   KA.     RNY   P.     PGP.   224     YNAD.   V.     V.   M.K.     EK.   CFI     V.   M.K.     EK.   CFI     P.GP.   224     YNAD.   V.     MINIMAL   MINIMAL     V.   V.     V.   V. <tr< td=""></tr<>
SFVpsc-hu.PFV-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.AG15-Tas SFVggo-hu.BAD468-Tas SFVggo-hu.BAV74 -Tas SFVggo-hu.BAK74 -Tas SFVcni-hu.AG16-Tas	WDPEVGTWVKYKPLRG I VGSAVF I MHKHDRNG SLVKPSTSRSEGPKPRPRH DPVLRCDMFEKHHKPRQKRPRRRS I 225     S. E.   E. K.     K.   P. S.K.     YNAD   F.     V. FNR.   V.     M.K.   EK.     CFI   P.KQ     YNAD   K.     V.   M.K.     EK.   CFI     YNAD   V.     M.K.   EK.     CFI   P.KQ     YNAD   V.     M.K.   EK.     CFI   P.KQ     YNAD   V.     M.K.   EK.     CFI   P.KQ     KA.   RNY     P.J.   PGP.     YNAD   V.     M.K.   EK.     CFI   P.KQ     KA.   RNY     P.G.   PGP.     YNAD   V.     M.K.   EK.     CFI   P.KQ     KA.   RNY     V.   M.K.     EK.   CFI     P.G.   P.G.     YNAD   V.
SFVpsc-hu.PFV-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.AG15-Tas SFVggo-hu.BAD468-Tas SFVggo-hu.BAV74 -Tas SFVggo-hu.BAK74 -Tas SFVcni-hu.AG16-Tas	WDPEVGI WVKYKPLRG I VGSAVF I MHKHDRNG SLVKPSTSRSEGPKPRPRH DPVLRCDMFEKHHKPRQKRPRRRS I 225
SFVpsc-hu.PFV-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.AG15-Tas SFVgto-hu.AG15-Tas SFVggo-hu.BAD468-Tas SFVggo-hu.BAK74 -Tas SFVcni-hu.AG16-Tas SFVcni-hu.AG16-Tas SFVpsc-hu.PFV-Tas SFVpre-Tas	WDPEVGIIWVKYKPLRGIVGSAVFIMHKHDRNGSLVKPSTSRSEGPKPRPRHDPVLRCDMFEKHHKPRQKRPRRRSI225
SFVpsc-hu.PFV-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.AG15-Tas SFVggo-hu.BAD468-Tas SFVggo-hu.BAV468-Tas SFVggo-hu.BAK74 -Tas SFVcni-hu.AG16-Tas SFVpsc-hu.PFV-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.BAD327-Tas	WDPEVGIIWVKYKPLRGIVGSAVFIMHKHDRNGSLVKPSTSRSEGPKPRPRHDPVLRCDMFEKHHKPRQKRPRRRSI225     S. E.   E. K.     K.   CP     K.   P. S.K.     YNAD.   F.     V. LN.   V.     MK.   EK.     CFI   P.KQ.     YNAD.   M.K.     K.   CFI     YNAD.   V.     M.K.   EK.     CFI   P.KQ.     KA.   RNY     P.GP.   224     YNAD.   M.K.     KA.   RNY     P.GP.   224     YNAD.   M.K.     KA.   RNY     M.K.   EK.     GEF   P.S.
SFVpsc-hu.PFV-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.AG15-Tas SFVggo-hu.BAV468-Tas SFVggo-hu.BAV468-Tas SFVggo-hu.BAV74 -Tas SFVcni-hu.AG16-Tas SFVptr-hu.AG16-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.BAD327-Tas	WDPEVGTWVKYKPLRGIVGSAVFIMHKHDRNGSLVKPSTSRSEGPKPRPRHDPVLRCDMFEKHHKPRQKRPRRRSI225     S.E.   E.K.     K.   E.K.     YNAD   F.R.     V.F.   F.Y.     YNAD   K.     V.F.   F.Y.     YNAD   K.     V.F.   F.Y.     YNAD   K.     V.F.   F.Y.     YNAD   K.     V.F.   K.     YNAD   K.     V.   M.K.     EK.   CFI     YNAD   V.     V.   M.K.     EK.   CFI     VAD   V.     M.K.   EK.     CFI   P.KQ     KA   RNY     V.MA   EK.     CFI   P.KQ     KA   RNY     P.P.   P.GP     YNAD   V.     M.K.   EK.     CFI   P.KQ      KA      RNY      S.WGMA      YNR     <
SFVpsc-hu.PFV-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.AG15-Tas SFVggo-hu.BAD468-Tas SFVggo-hu.BAV74 -Tas SFVggo-hu.BAV74 -Tas SFVcni-hu.AG16-Tas SFVpsc-hu.PFV-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.AG15-Tas SFVptr-hu.BAD427-Tas	WDPEVGIIWVKYKPLRGIVGSAVFIMHKHDRNGSLVKPSTSRSEGPKPRPRHDPVLRCDMFEKHHKPRQKRPRRRSI225     S.E.   E.K.     K.   F.Y.     K.   F.Y.     YNAD   F.R.     V.   M.K.     K.   K.     YNAD   K.     V.   M.K.     K.   K.     YNAD   V.     M.K.   EK.     CFI   P.KQ     YNAD   V.     M.K.   EK.     CFI   P.KQ     YNAD   V.     M.K.   EK.     CFI   P.KQ     YNAD.   V.     M.K.   EK.     CFI   P.KQ     YNAD.   V.     M.K.   EK.     CFI   P.KQ     YNAD.   V.     M.K.   EK.     CFI   P.KQ     MINIMAL   KA.     RNY   P.     PGP   224     MINIMAL   M.K.     MINIMAL   S.P.     MIN   M.K.
SFVpsc-hu.PFV-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.AG15-Tas SFVggo-hu.BAD468-Tas SFVggo-hu.BAD468-Tas SFVggo-hu.BAK74 -Tas SFVcni-hu.AG16-Tas SFVpsc-hu.PFV-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.AG15-Tas SFVptr-hu.BAD327-Tas SFVggo-Tas	WDPEVGII WVKYKPLRG I VGSAVF I MHKHDRNG SLVKPSTSRSEGPKPRPRH DPVLRCDMFEKHHKPRQKRPRRRS I 225     .S.E.
SFVpsc-hu.PFV-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.AG15-Tas SFVggo-hu.BAD468-Tas SFVggo-hu.BAV468-Tas SFVggo-hu.BAV74 -Tas SFVcni-hu.AG16-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.BAD327-Tas SFVptr-hu.BAD468-Tas SFVggo-hu.BAD468-Tas	WDPEVGTWVKYKPLRGIVGSAVFIMHKHDRNGSLVKPSTSRSEGPKPRPRHDPVLRCDMFEKHHKPRQKRPRRRSI225     S.E.   E.K.   CP.R.   P.S.K.   225     K.   F.Y.   F.Y.   E.K.   225     YNAD.   Y.F.   F.Y.   K.K.   E.K.   225     YNAD.   Y.K.   F.Y.   K.K.   E.K.   225     YNAD.   Y.F.   Y.K.   E.K.   225     YNAD.   Y.K.N.   Y.K.   F.Y.   K.K.   224     YNAD.   Y.K.   K.K.   CFI.   P.KQ.   KA.RNY.   P. PGP. 224     YNAD.   Y.K.   K.K.   CFI.   P.KQ.   KA.RNY.   P. PGP. 224     YNAD.   Y.K.   K.K.   CFI.   P.KQ.   KA.RNY.   P. PGP. 224     YNAD.   Y.K.   K.K.   CFI.   P.KQ.   KA.RNY.   P. PGP. 224     H.N.L.   L.MG.   DL.V.HTLR.YNRLSTL.G.G.   P.V.T.AN.R.YREMQVVEA.P.S.WGMA 225   WGMA 225     Minimal Activation motif   DNESCASSSD-TMANEPGSLCTNPLWNPGPLLSGLLEESSNLPNLEVHMSGGPFWEEVYGDSILGPPSGSGEHSVL 300   300

#### Supplementary figure 2: Percent identity and functional motifs in SFV LTRs.

ĺ		1	2	3	4	5	6	7	8	9
SFVpsc.hu-PFV-LTR	1		54,18	87,98	90,63	90,41	43,82	63,21	38,26	43,97
SFVpsc.hu-HSRV13	2	54,18		46,47	48,22	48,00	54,97	36,24	47,26	27,39
SFVpve-LTR	3	87,98	46,47		88,81	88,66	43,79	62,79	38,19	43,64
SFVptr.hu-AG15-LTR	4	90,63	48,22	88,81		99,16	44,21	63,68	38,46	43,60
SFVptr.hu-BAD327-LTR	5	90,41	48,00	88,66	99,16		44,07	63,27	38,37	44,01
SFVggo-LTR	6	43,82	54,97	43,79	44,21	44,07		64,05	82,31	30,63
SFVggo.hu-BAD468-LTR	7	63,21	36,24	62,79	63,68	63,27	64,05		56,39	40,42
SFVggo.hu-BAK74-LTR	8	38,26	47,26	38,19	38,46	38,37	82,31	56,39		28,33
SFVcni.hu-AG16-LTR	9	43,97	27,39	43,64	43,60	44,01	30,63	40,42	28,33	

#### A. 5'LTR-U3 region: percent identity

#### B. 5'LTR-U3 region (last 70 nt): percent identity

		1	2	3	4	5	6	7	8	9
u-PFV-LTR	1		95,71	83,10	87,14	85,71	66,20	66,20	67,61	45,07
hu-HSRV13	2	95,71		81,69	85,71	84,29	67,61	67,61	69,01	43,66
SFVpve-LTR	3	83,10	81,69		87,32	87,32	67,61	67,61	69,01	45,83
I-AG15-LTR	4	87,14	85,71	87,32		97,14	67,61	67,61	69,01	43,66
AD327-LTR	5	85,71	84,29	87,32	97,14		67,61	67,61	69,01	46,48
FVggo-LTR	6	66,20	67,61	67,61	67,61	67,61		97,10	92,75	44,44
AD468-LTR	7	66,20	67,61	67,61	67,61	67,61	97,10		92,75	47,22
BAK74-LTR	8	67,61	69,01	69,01	69,01	69,01	92,75	92,75		44,44
I-AG16-LTR	9	45,07	43,66	45,83	43,66	46,48	44,44	47,22	44,44	

SFVpsc.hu-PFV-LTF SFVpsc.hu-HSRV13 SFVpve-LTF SFVptr.hu-AG15-LTF SFVptr.hu-BAD327-LTF SFVggo.hu-BAD468-LTF SFVggo.hu-BAD468-LTF SFVggo.hu-BAK74-LTF SFVggo.hu-AG16-LTF

#### C. 5'LTR-R region: percent identity

		1	2	3	4	5	6	7	8	9
V-LTR	1		100,00	93,26	91,19	91,19	82,99	82,99	81,54	69,37
SRV13	2	100,00		93,26	91,19	91,19	82,99	82,99	81,54	69,37
ve-LTR	3	93,26	93,26		97,30	97,30	88,71	88,71	87,17	68,47
15-LTR	4	91,19	91,19	97,30		98,91	89,13	89,13	88,65	66,22
27-LTR	5	91,19	91,19	97,30	98,91		89,13	89,13	88,65	66,67
go-LTR	6	82,99	82,99	88,71	89,13	89,13		98,91	93,48	66,22
8-LTR	7	82,99	82,99	88,71	89,13	89,13	98,91		93,48	66,22
4-LTR	8	81,54	81,54	87,17	88,65	88,65	93,48	93,48		66,22
16-LTR	9	69,37	69,37	68,47	66,22	66,67	66,22	66,22	66,22	

SFVpsc.hu-PFV-LTI SFVpsc.hu-HSRV1 SFVpve-LTI SFVptr.hu-AG15-LTI SFVptr.hu-BAD327-LTI SFVggo.hu-BAD468-LTI SFVggo.hu-BAK74-LTI SFVggo.hu-BAK74-LTI SFVcni.hu-AG16-LTI

#### D. 5'LTR-U5 region: percent identity

		1	2	3	4	5	6	7	8	9
nu-PFV-LTR	1		98,69	95,45	91,56	90,91	66,88	77,71	78,98	76,10
hu-HSRV13	2	98,69		96,71	92,76	92,11	67,74	78,71	80,00	77,07
SFVpve-LTR	3	95,45	96,71		94,08	93,42	68,39	79,35	80,00	78,98
I-AG15-LTR	4	91,56	92,76	94,08		99,34	67,74	78,71	78,06	79,62
AD327-LTR	5	90,91	92,11	93,42	99,34		67,10	78,06	77,42	78,98
FVggo-LTR	6	66,88	67,74	68,39	67,74	67,10		85,81	82,58	67,09
AD468-LTR	7	77,71	78,71	79,35	78,71	78,06	85,81		93,55	77,22
BAK74-LTR	8	78,98	80,00	80,00	78,06	77,42	82,58	93,55		76,58
I-AG16-LTR	9	76,10	77,07	78,98	79,62	78,98	67,09	77,22	76,58	

SFVpsc.hu-PFV-LTF SFVpsc.hu-HSRV13 SFVpve-LTF SFVptr.hu-AG15-LTF SFVptr.hu-BAD327-LTF SFVggo.hu-BAD468-LTF SFVggo.hu-BAK74-LTF SFVggo.hu-BAK74-LTF SFVcni.hu-AG16-LTF



### Supplementary figure 2-continued

SFVpsc.hu-PFV-LTR SFVpsc.hu-HSRV13 SFVpsc.hu-BAD327-LTR SFVptr.hu-BAD327-LTR SFVggo.hu-BAD468-LTR SFVggo.hu-BAD468-LTR SFVggo.hu-BAK74-LTR	CTTTGCTA - TCCCTGAAGGAAGCATAGCTCTTCAGGTAAAGAGGGCCAGTAT - TAAAAGAGCTACCCTTCCTTTTC - ATATAAGGATCGAAACCTGCT 77 	78 99 76 78 79 14 69 34 45
SFVpsc.hu-PFV-LTR SFVpsc.hu-HSRV13 SFVpre-LTR SFVptr.hu-BAD327-LTR SFVptr.hu-AG15-LTR SFVggo.hu-BAD468-LTR SFVggo.hu-BAD468-LTR SFVggo.hu-BAC74-LTR	TACGT - TTTACT - TTAATAAAGTTAAGTTTTAAGTTTTAACAGGAAATGCTCTTAGGCAGAAGGTAGCTCCCTCGACTGGGTGACAAGGAAGAAACCATT 87	76 06 74 75 76 14 68 34 26
SFVpsc.hu-PFV-LTR SFVpsc.hu-HSRV13 SFVpre-LTR SFVptr.hu-BAD327-LTR SFVgpo.hu-BAD348-LTR SFVggo.hu-BAD468-LTR SFVggo.hu-BAC74-LTR SFVggo.hu-AG16-LTR	CAGGAAGTGCTTCCTTCTGCTCGGGGAGATACATGAG TATACAGTAGTTCGAATCCTGT GTGCTGATGATGTCTTCTCGGCTTTTT GTGACATCA 97 T	71 06 69 71 73 14 66 34 17
SFVpsc.hu-PFV-LTR SFVpsc.hu-HSRV13 SFVptr.hu-BA0327-LTR SFVptr.hu-BA0327-LTR SFVggo.hu-BA0468-LTR SFVggo.hu-BA0468-LTR SFVggo.hu-BAK74-LTR SFVggo.hu-AG16-LTR	CAAATGTTACTTAGAGGTAGC-TTTCTGAGAGGTTTATACCTCAG-AAGGAGTGTGGCTAATGCTGGTAAGGCACCTTTCTATCAGTACAATCAAGCCCA 10   50     T.   AAC.C.   A.   A.   7.   10    G.A.C.   T.C.T.A.   T.   G.   A.   AAA.   7.   10    G.A.C.   T.C.T.A.   T.   G.   A.   AA.   T.T.T.T.   10    G.G.A.C.   T.C.T.A.   T.   G.   A.   AA.   T.T.T.T.   10    G.G.G.G.G.G.G.G.G.G.G.G.G.G.G.G.G.G	069 069 070 072 14 063 34 010
SFVpsc.hu-PFV-LTR SFVpsc.hu-HSRV13 SFVptr.hu-BA0327-LTR SFVptr.hu-AG15-LTR SFVggo-hu-BA0468-LTR SFVggo.hu-BA0468-LTR SFVggo.hu-BA0468-LTR	TTCCTCCCCATGT TCTCAGGGTGTGTGCGGCGTAAGATCGAATCCCCACACACCTGGGAACTTGCT - TATTGCATAATAATTTTATTAGTCATA - T	163 17 162 164 166 64 162 41 063
SFVpsc.hu-PFV-LTR SFVpsc.hu-HSRV13 SFVptre-LTR SFVptr.hu-BAD327-LTR SFVptr.hu-AG15-LTR SFVggo.hu-BAD468-LTR SFVggo.hu-BAD468-LTR SFVggo.hu-BAK74-LTR	AGAAAA   TAATATA   GGATAAGGTATAAGGATTAAGGATTAAGGTATGAGGTGTGGGCTCAACACGTAGGGTGACAAGAAAATCTACTGTAAT   AGGACACAACAC   12	260 14 260 261 263 62 261 11 163
SFVpsc.hu-PFV-LTR SFVpsc.hu-HSRV13 SFVptr.hu-BAD327-LTR SFVptr.hu-AG15-LTR SFVggo.hu-BAD468-LTR SFVggo.hu-BAD468-LTR SFVggo.hu-BAK74-LTR	CTCTAAAGTTGCC CGTGGGAAGGTGAAGTGAGATCGAAT CTTTCCT TAACGCAGACAGCTTTTT	342 96 342 343 345 60 360 88 251
SFVpsc.hu-PFV-LTR SFVpsc.hu-HSRV13 SFVpre-LTR SFVptr.hu-BAD327-LTR SFVgo-LTR SFVggo-LTR SFVggo-hu-BAD468-LTR SFVggo-hu-BAX74-LTR SFVgoi.hu-AG16-LTR	TTTAAGGAATACTATA   GGAATAGATTGATAGTTTAACAATGATAGAAATAGTATATAGGGATAGTTTC   TATABox   + 1 (R)     TTTAAGGAATACTATA   GGAATAGATTGATAGTTTAACAATGATAGAAATAGTATATAGGGATAGTTTC   TAGGATGC   TAGGATGC     G. C. A, TG.   G. T.   G. C. A, TG.   G. T.   A.     G. T. C. T.   G. C. A, TG.   G. C. A, TG.   A.     AGGAATC.   AGGTAT.GTA.   A.   A.     AGGAATC.   AGGTAT.GTA.   A.   A.     AGGAATC.   AGGTAT.GTA.   A.   A.     AGGAATC.   A.   A	